

LAW OFFICES OF LEONA L. LAUDER

INTELLECTUAL PROPERTY - SPECIALIZING IN BIOTECHNOLOGICAL AND CHEMICAL PATENTS
465 CALIFORNIA STREET, SUITE 450
SAN FRANCISCO, CALIFORNIA 94104-1840
TELEPHONE (415) 981-2034 FAX (415) 981-0332

RECEIVED
CENTRAL FAX CENTER

MAY 18 2005

FACSIMILE MESSAGE

TO : Examiner Anne L. Holleran
Group Art Unit: 1642
USPTO

FROM: Leona L. Lauder

NO. OF PAGES FOLLOWING: 19

FAX NO.: 703-872-9306

DATE : May 18, 2005

IMPORTANT NOTICE

The information contained in this facsimile message may include attorney-client privileged and confidential information intended only for the use of the individual or entity named above and others who have been specifically authorized to receive it. If you are not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone (415-981-2034) and return the original transmission to us by mail without making a copy. Thank you.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bruce M. Bowman Group: 1600

Serial No.: 09/480,389 Group Art Unit: 1642

Filed : January 11, 2000 Examiner: A. Holleran

For : Immunoassays to Detect Diseases or Disease
Susceptibility Traits

RECEIVED
MAY 19 2005
OIFE/JCWS

Response under 37 CFR 1.116
Expedited Procedure -
Examining Group 1600

Certification of Facsimile Transmission

I hereby certify that this paper and the documents referred to as attached therein are being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Denise Ortega
Name

RECEIVED
CENTRAL FAX CENTER

May 18, 2005
Date

Denise Ortega
Signature

MAY 18 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :	Bruce M. Bowman	Group: 1600
Serial No.:	09/480,389	Group Art Unit: 1642
Filed :	January 11, 2000	Examiner: A. Holleran
For :	Immunoassays to Detect Diseases or Disease Susceptibility Traits	

AMENDMENT TRANSMITTAL

MAIL STOP AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is a response to the final office action mailed from the U.S. Patent and Trademark Office on March 18, 2005

No fee should be required for the accompanying response. The fee for claims has been calculated as shown below:


	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	27	MINUS	50	0	X \$ 50	\$ 0.00
INDEP.	1	MINUS	3	0	X \$ 200	\$ 0.00

[] FIRST PRESENTATION OF MULTIPLE DEP. CLAIM + \$360 \$ 0.00

TOTAL \$ 0.00

However, should any additional fees be determined to be necessary in connection with this paper, Applicants respectfully request that any such additional fees be charged to Deposit Account No. 12-0615.

Respectfully submitted,


Leona L. Lauder
Attorney for Applicants
Registration No. 30,863

Dated: May 18, 2005

RECEIVED
CENTRAL FAX CENTER

MAY 18 2005

Response under 37 CFR 1.116
Expedited Procedure –
Examining Group 1600

Certification of Facsimile Transmission

I hereby certify that this paper and the documents referred to as attached therein are being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Denise Ortega
Name

May 18, 2005
Date:

Denise Ortega
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bruce M. Boman Group: 1600
Serial No : 09/480,389 Group Art Unit: 1642
Filed : January 11, 2000 Examiner: Anne L. Holleran
For : Immunoassays to Detect Diseases or Disease Susceptibility Traits

AMENDMENT AFTER FINAL
UNDER 37 CFR 1.116

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Amendment to the above-identified application is in response to the Final Office Action mailed from the U.S. Patent and Trademark Office (PTO) on March 18, 2005 and is being made within the two month period from the mailing of the Final Office Action. Applicants respectfully request that this Amendment After Final be

entered in accordance with 37 CFR § 116(a) and with the Manual of Patent Examining Procedure (MPEP) §§ 714.12 and 714.13.

Applicants respectfully submit that the instant Amendment After Final does not raise any new issues and presents the rejected claims "in condition for allowance." [MPEP § 714.12.] Detailed reasoning supporting the absence of any new issues and the allowability of the claims as amended follows below after the Remarks section, which section shows support in the Specification for the claim amendments. Thus, Applicants respectfully request that this Amendment After Final be entered, and that the claims as amended be allowed.